Last €2.11 EUR
Change Today +0.015 / 0.71%
Volume 56.8K
COX On Other Exchanges
EN Paris
As of 11:35 AM 08/21/14 All times are local (Market data is delayed by at least 15 minutes).

nicox sa (COX) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/11/13 - €3.03
52 Week Low
08/6/14 - €1.71
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NICOX SA (COX)

Related News

No related news articles were found.

nicox sa (COX) Related Businessweek News

View More BusinessWeek News

nicox sa (COX) Details

NicOx S.A. develops a portfolio of therapies and diagnostic tools to enhance sight in the United States, Europe, and internationally. It provides AdenoPlus a diagnostic test that offers eyecare professionals to diagnose and manage patients with an acute red eye. The company’s pipeline product, Latanoprostene bunod, is in Phase III clinical trials for the treatment of glaucoma and ocular hypertension. In addition, it is engaged in the research and development of nitric oxide steroids for the treatment of back and front of the eye disease; and NO-donors for eye disorder applications. Further, the company develops Naproxcinod, an anti-inflammatory candidate that is in regulatory review with the US Food and Drug Administration for the treatment of signs and symptoms of osteoarthritis; nitric oxide for cardiovascular indications; and NCX 1047, a dermatology anti-inflammatory drug-candidate, which is in preclinical stage of development. NicOx S.A. has collaboration with Bausch + Lomb, Merck, and Grupo Ferrer Internacional S.A. The company was founded in 1996 and is headquartered in Sophia Antipolis, France.

98 Employees
Last Reported Date: 04/2/14
Founded in 1996

nicox sa (COX) Top Compensated Officers

Co-Founder, Chairman and Chief Executive Offi...
Total Annual Compensation: €417.7K
Compensation as of Fiscal Year 2013.

nicox sa (COX) Key Developments

Nicox to Co-Promote Latanoprostene Bunod in US with Bausch + Lomb

Nicox SA announced its decision to exercise rights to co-promote latanoprostene bunod in the US with Bausch + Lomb. According to the terms of a licensing agreement signed by the two companies in 2010, Nicox retains the possibility to co-promote latanoprostene bunod in the US.

Nicox S.A. Announces Board Changes

Nicox S.A. announced the co-option of Adrienne Graves and Luzi von Bidder to its Board of Directors. Graves and von Bidder will replace Vaughn Kailian, who has been a member of the Board since 2001, and Vince Anido. Vaughn Kailian has informed Nicox of his decision to step down from the Board of Directors with effect from August 11, 2014, for personal reasons which make it difficult for him to continue his commitment to Nicox. Vince Anido, who joined the Board in June 2013, has decided to step down from Nicox's Board due to his increasing responsibilities at Aerie Pharmaceuticals Inc., with effect from August 6, 2014. The Board has decided to co-opt Adrienne Graves, and Luzi von Bidder as members of the Board with effect from August 8, 2014 and August 11, 2014, respectively. These co-options will be submitted to Nicox's shareholders for approval at the General Meeting to be convened in the Fall to vote on the proposed acquisition of Aciex Therapeutics Inc. The company's Board of Directors also intends to propose to such General Meeting the appointment of Les Kaplan, Executive Chairman of Aciex Therapeutics Inc. and former Executive Vice President and President, Research and Development of Allergan Inc., as member of the Board, subject to the prior approval by Nicox's shareholders of the acquisition of Aciex Therapeutics Inc. Adrienne L. Graves, Ph.D, was President and Chief Executive Officer of Santen Inc., from 2002 to 2010. Luzi A. von Bidder was until recently Chairman of the Swiss-listed company Acino Holding AG. Les Kaplan, PhD, is the Executive Chairman of Aciex Therapeutics Inc. He was previously Executive Vice President of Allergan Inc.

Aciex Therapeutics Inc., Nicox SA - M&A Call

Nicox to acquire Aciex Therapeutics, Inc


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
COX:FP €2.11 EUR +0.015

COX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for COX.
View Industry Companies

Industry Analysis


Industry Average

Valuation COX Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NICOX SA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at